ZVRA · Healthcare · $648M
$10.97-3.26%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“MIPLYFFA가 NPC(니만-픽병 C형) 치료 공식 임상 가이드라인에 처음으로 등재됐어요.”
In the company's words · 2026 1분기 earnings call